INT106097

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.62
First Reported 2002
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 20
Total Number 24
Disease Relevance 12.01
Pain Relevance 19.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
bowel 3
anterior 1
nucleus 1
POA 1
pr (Mus musculus)
Pain Link Frequency Relevance Heat
Oxycodone 1460 100.00 Very High Very High Very High
narcan 717 100.00 Very High Very High Very High
Opioid 326 99.54 Very High Very High Very High
analgesia 113 99.28 Very High Very High Very High
withdrawal 34 99.08 Very High Very High Very High
Dynorphin 22 98.60 Very High Very High Very High
Bioavailability 28 97.48 Very High Very High Very High
antagonist 25 96.48 Very High Very High Very High
opioid receptor 36 96.04 Very High Very High Very High
Lasting pain 85 95.60 Very High Very High Very High
Disease Link Frequency Relevance Heat
Constipation 387 99.96 Very High Very High Very High
Disease 106 99.84 Very High Very High Very High
Cancer 356 99.52 Very High Very High Very High
Substance Withdrawal Syndrome 4 99.44 Very High Very High Very High
Metastasis 74 97.92 Very High Very High Very High
Leiomyosarcoma 26 96.88 Very High Very High Very High
Aids-related Complex 8 95.64 Very High Very High Very High
Pain 431 95.60 Very High Very High Very High
Synovial Sarcoma 16 95.52 Very High Very High Very High
Sarcoma 101 94.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
During randomisation 265 patients on a stable OXY PR dose (60-80 mg/day) and with OIC were included in the full analysis population to receive OXN PR or OXY PR alone.
Localization (receive) of OXN PR
1) Confidence 0.62 Published 2009 Journal Expert Opin Pharmacother Section Body Doc Link 19243306 Disease Relevance 0.26 Pain Relevance 0
During randomisation 265 patients on a stable OXY PR dose (60-80 mg/day) and with OIC were included in the full analysis population to receive OXN PR or OXY PR alone.
Localization (receive) of PR
2) Confidence 0.54 Published 2009 Journal Expert Opin Pharmacother Section Body Doc Link 19243306 Disease Relevance 0.26 Pain Relevance 0
Oxycodone PR/naloxone PR dose ratio
Localization (ratio) of PR associated with oxycodone and narcan
3) Confidence 0.27 Published 2008 Journal International Journal of Clinical Practice Section Body Doc Link PMC2658020 Disease Relevance 0 Pain Relevance 0.28
Oxycodone PR/naloxone PR dose ratio
Localization (ratio) of PR associated with oxycodone and narcan
4) Confidence 0.27 Published 2008 Journal International Journal of Clinical Practice Section Body Doc Link PMC2658020 Disease Relevance 0 Pain Relevance 0.28
This randomised clinical trial evaluated patient assessment of the efficacy and tolerability of oral prolonged-release (PR) oxycodone when co-administered with oral naloxone PR.


Localization (release) of PR associated with oxycodone and narcan
5) Confidence 0.26 Published 2008 Journal International Journal of Clinical Practice Section Abstract Doc Link PMC2658020 Disease Relevance 0.45 Pain Relevance 0.61
Combination therapy with prolonged-release (PR) oxycodone plus PR naloxone has been shown to provide effective analgesia while preventing or reducing constipation.
Localization (prolonged-release) of PR associated with oxycodone, constipation, narcan and analgesia
6) Confidence 0.23 Published 2009 Journal Pharmacology Section Abstract Doc Link 18957874 Disease Relevance 0.79 Pain Relevance 1.41
Combination therapy with prolonged-release (PR) oxycodone plus PR naloxone has been shown to provide effective analgesia while preventing or reducing constipation.
Localization (prolonged-release) of PR associated with oxycodone, constipation, narcan and analgesia
7) Confidence 0.23 Published 2009 Journal Pharmacology Section Abstract Doc Link 18957874 Disease Relevance 0.78 Pain Relevance 1.41
METHODS: We surveyed 250 family physicians, family medicine residents, and nurses attending oncology educational symposia to determine their knowledge of PR.
Spec (determine) Localization (knowledge) of PR
8) Confidence 0.23 Published 2008 Journal J Cancer Educ Section Body Doc Link 18709586 Disease Relevance 0.09 Pain Relevance 0
In these systems, keratin promoters are used to restrict the expression of the RU486 inducible Cre recombinase-PR fusion protein; upon treatment with the RU486 activator, the Cre recombinase-PR fusion protein translocates to the nucleus and excises sequences between Lox P sites, facilitating conditional genetic manipulation of target genes 22.
Localization (translocates) of PR in nucleus
9) Confidence 0.17 Published 2010 Journal International Journal of Biological Sciences Section Body Doc Link PMC2815352 Disease Relevance 0.22 Pain Relevance 0
AE: adverse event; BFI: Bowel Function Index; CIs: confidence intervals; FDC: fixed-dose combination; GI: gastrointestinal; IR: immediate release; Non-LOCF: non-last observation carried forward; OIC: Opioid-induced constipation; PR: prolonged release; SAE: serious adverse event; TSQM: Treatment Satisfaction Questionnaire for Medication; WHO: World Health Organisation

Competing interests

Localization (release) of PR in Bowel associated with oxycodone, constipation and opioid
10) Confidence 0.08 Published 2010 Journal BMC Clin Pharmacol Section Body Doc Link PMC2955588 Disease Relevance 0.64 Pain Relevance 1.83
A prolonged-release (PR) formulation of oral naloxone can reveal a reduction of these risks.
Localization (release) of PR associated with narcan
11) Confidence 0.08 Published 2010 Journal BMC Clin Pharmacol Section Body Doc Link PMC2955588 Disease Relevance 0.50 Pain Relevance 1.65
Results from a study which compared pharmacokinetics data from a single-dose and multiple-dose bioequivalence study of fixed-dose combination (FDC) oxycodone prolonged-release (PR)/naloxone PR versus separate formulations of oxycodone PR and naloxone PR administered concurrently in healthy volunteers, demonstrated that the co-administration of oxycodone PR and naloxone PR in a FDC does not significantly affect the bioavailability of either of its constituents [20].
Localization (release) of PR associated with oxycodone, narcan and bioavailability
12) Confidence 0.07 Published 2010 Journal BMC Clin Pharmacol Section Body Doc Link PMC2955588 Disease Relevance 0.28 Pain Relevance 2.71
Results from a study which compared pharmacokinetics data from a single-dose and multiple-dose bioequivalence study of fixed-dose combination (FDC) oxycodone prolonged-release (PR)/naloxone PR versus separate formulations of oxycodone PR and naloxone PR administered concurrently in healthy volunteers, demonstrated that the co-administration of oxycodone PR and naloxone PR in a FDC does not significantly affect the bioavailability of either of its constituents [20].
Localization (release) of PR associated with oxycodone, narcan and bioavailability
13) Confidence 0.07 Published 2010 Journal BMC Clin Pharmacol Section Body Doc Link PMC2955588 Disease Relevance 0.28 Pain Relevance 2.73
A substantial number of patients receiving bevacizumab in this trial, while not having sufficient tumor shrinkage to be classified as having a PR or complete response, had mixed tumor responses (Yang 2004).
Localization (response) of PR associated with cancer
14) Confidence 0.07 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721410 Disease Relevance 0.52 Pain Relevance 0.04
When the changes in the sum of the diameters are not sufficient to qualify for PR or PD, the objective response is defined as stable disease (SD).


Localization (qualify) of PR associated with disease
15) Confidence 0.04 Published 2010 Journal Target Oncol Section Body Doc Link PMC2929340 Disease Relevance 0.63 Pain Relevance 0.07
2 PR, 1 NC, and 1 progression were seen leading to an
Localization (progression) of PR
16) Confidence 0.04 Published 2006 Journal Sarcoma Section Body Doc Link PMC1510952 Disease Relevance 1.57 Pain Relevance 0
In 1971, Kagan et al observed different responses (CR, PR, and NC)
Localization (responses) of PR
17) Confidence 0.04 Published 2006 Journal Sarcoma Section Body Doc Link PMC1510952 Disease Relevance 1.47 Pain Relevance 0
The aim of this study was to assess safety and efficacy of fixed combination oxycodone prolonged release (PR)/naloxone PR in terms of both analgesia and improving opioid-induced bowel dysfunction (OIBD) and associated symptoms, such as opioid-induced constipation (OIC), in adults with chronic non-cancer pain.


Localization (release) of PR in bowel associated with oxycodone, constipation, cancer pain, narcan, opioid and analgesia
18) Confidence 0.03 Published 2010 Journal International Journal of Clinical Practice Section Abstract Doc Link PMC2948431 Disease Relevance 0.64 Pain Relevance 1.11
Results from a pharmacokinetic study in healthy subjects demonstrated that co-administration of oxycodone prolonged release (PR)/naloxone PR in a fixed dose combination does not significantly affect the bioavailability of either of its constituents (20).
Localization (release) of PR associated with oxycodone, narcan and bioavailability
19) Confidence 0.03 Published 2010 Journal International Journal of Clinical Practice Section Body Doc Link PMC2948431 Disease Relevance 0.46 Pain Relevance 1.62
The aim of this study was to assess safety and efficacy of fixed combination oxycodone prolonged release (PR)/naloxone PR in terms of both analgesia and improving opioid-induced bowel dysfunction (OIBD) and associated symptoms, such as opioid-induced constipation (OIC), in adults with chronic non-cancer pain.


Localization (release) of PR in bowel associated with oxycodone, constipation, cancer pain, narcan, opioid and analgesia
20) Confidence 0.03 Published 2010 Journal International Journal of Clinical Practice Section Abstract Doc Link PMC2948431 Disease Relevance 0.64 Pain Relevance 1.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox